Clarius Group LLC Grows Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Clarius Group LLC raised its position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 88.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,500 shares of the company's stock after acquiring an additional 100,000 shares during the quarter. Clarius Group LLC owned approximately 0.09% of Sana Biotechnology worth $357,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its position in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after acquiring an additional 10,548 shares in the last quarter. Cerity Partners LLC acquired a new position in shares of Sana Biotechnology during the fourth quarter worth about $25,000. Syon Capital LLC acquired a new position in shares of Sana Biotechnology during the fourth quarter worth about $27,000. Pallas Capital Advisors LLC acquired a new position in shares of Sana Biotechnology during the first quarter worth about $29,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Sana Biotechnology during the fourth quarter worth about $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Stock Performance

NASDAQ SANA traded down $0.01 on Monday, reaching $2.60. The stock had a trading volume of 16,139,476 shares, compared to its average volume of 3,657,335. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.40. The business's 50-day moving average price is $2.09 and its 200 day moving average price is $2.34. The stock has a market cap of $586.25 million, a P/E ratio of -2.95 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. On average, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Tuesday, March 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a report on Thursday, April 24th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.